drugset / Trial / NCT03662282

Omegaven as Alternative Parenteral Fat Nutrition

NCT03662282

Phase 3 Completed 2 enrolled University of South Florida
NaSingle-groupOpen-labelTreatment

Summary

To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis

Timeline

Start
2018-10-23
Primary completion
2019-01-07
Completion
2019-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Omegaven Other / unclassified 0.5 unknown Intravenous
Subject Omegaven Other / unclassified 1 unknown Intravenous